Assessment of therapeutic response in patients with metastatic bone disease
| Autor: | Mark Clemons, Huy Tram N Nguyen, Andrew R Clamp, Sarah Danson, David E.C. Cole |
|---|---|
| Rok vydání: | 2004 |
| Předmět: |
Oncology
medicine.medical_specialty Pathology Bone disease Disease Response Bone Neoplasms Bone resorption Bone remodeling Absorptiometry Photon Internal medicine Biomarkers Tumor medicine Humans Bone cancer business.industry Cancer medicine.disease Magnetic Resonance Imaging Resorption Treatment Outcome Bone Remodeling Tomography X-Ray Computed business Type I collagen Tomography Emission-Computed |
| Zdroj: | The Lancet Oncology. 5:607-616 |
| ISSN: | 1470-2045 |
| DOI: | 10.1016/s1470-2045(04)01596-7 |
| Popis: | Metastatic bone disease is common in cancer patients and causes substantial disease-related morbidity and mortality. However, several effective treatments are available for the management of these patients. Bisphosphonates, which inhibit osteoclast-mediated resorption of bone matrix, are especially important because they decrease the incidence of skeletal-related events in many tumour types and can complement antineoplastic therapies. At present, assessment of treatment for bone metastases is hindered by a lack of effective, rapid methods to measure disease response. We discuss the difficulties of current measures of response assessment and describe the development of new radiological and biochemical markers of bone metastases. Assays that detect type I collagen telopeptides as markers of bone resorption seem to be most promising at present. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|